The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis

Ling Liang1,2 | Xianghua Hou3,4 | Kevin R. Bainey5 | Yanlin Zhang3,4 | Wayne Tymchak5 | Zhongquan Qi6 | Weihua Li1,2 | Hoan Linh Banh7

1Department of Cardiology, The First Affiliated Hospital of Xiamen University, Xiamen, China
2Department of Cardiology, First Clinical Medical College of Fujian Medical University, Fuzhou, China
3Department of Nephrology, The First Affiliated Hospital of Xiamen University, Xiamen, China
4Department of Nephrology, First Clinical Medical College of Fujian Medical University, Fuzhou, China
5Division of Cardiology, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
6Institute of Organ Transplantation, Xiamen University, Xiamen, China
7Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada

Correspondence
Zhongquan Qi, Institute of organ transplantation, Xiamen University, Xiamen, China.
Email: zqqi@xmu.edu.cn
Weihua Li, Department of Cardiology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Email: liweihuaxm@sina.com

Abstract
Hyperuricemia coincides with coronary artery calcification (CAC) development, but the role of serum uric acid (SUA) as a risk factor for CAC remains unclear. The objective of this study was to gain an insight into the association between SUA and CAC in adults by performing a meta-analysis. MEDLINE, EMBASE, the Cochrane Library, and EBSCO (CINAHL) were searched for relevant observational studies published until 2 June 2019. Studies were included only if they reported data on CAC presence (Agatston score > 0) or progression related to hyperuricemia in subclinical adult patients. The pooled estimates of crude and adjusted odds ratios (ORs) and 95% confidence interval (CI) were calculated to evaluate the association between CAC presence or progression and hyperuricemia. A total of 11 studies were identified involving 11,108 adults. The pooled OR based on the frequency of CAC presence showed that patients in the high SUA group had 1.806-fold risk for developing CAC (95% CI: 1.491-2.186) under the minimal threshold of hyperuricemia (more than 6 mg/dL or 357 μmol/L). When SUA levels were analyzed as categorical variables, the pooled estimate of adjusted ORs was 1.48 (95% CI: 1.23-1.79) for CAC presence. Additionally, for each increase of 1 mg/dL of SUA level, the risk of CAC progression was increased by 31% (95% CI: 1.15-1.49) with an average follow-up duration ranged from 4.6 to 6.1 years. Hyperuricemia is closely associated with increased risk of CAC development and CAC progression in asymptomatic patients.

KEYWORDS
coronary artery calcification, hyperuricemia, meta-analysis

1 | INTRODUCTION

Coronary artery calcification (CAC) is a marker of coronary atherosclerosis1 and is associated with major adverse cardiovascular events.

CAC can be measured by chest computerized tomography (CT) and quantified by the Agatston Score.2 This method is a validated gauge of atherosclerotic plaque burden and able to provide noninvasive quantitative information of all coronary artery vessels. Its presence and progression correlate not only with the development and extent...
of coronary heart disease (CHD), but also with CHD mortality and all-cause mortality.

Hyperuricemia may increase cardiovascular risk by inducing endothelial dysfunction, oxidation stress, and inflammation. Studies have showed that increased serum uric acid (SUA) level is associated with adverse clinical events and mortality with acute coronary syndromes as well as stable ischemic heart disease. However, a few Mendelian randomization studies have demonstrated inconsistent results examining the causal relationship of increased serum urate concentration and CHD. Similarly, the role of SUA as a risk factor for CAC remains controversial as some studies have reported a significant association between SUA and CAC, while others suggest no significant association. Given these inconsistencies, the primary objective of this systematic review is to assess the association between SUA and CAC in adult patients.

2 | METHOD

The current systematic review was performed in accordance with the checklist of meta-analysis of observational studies in epidemiology. A review protocol was not mandated as part of the systematic review.

2.1 | Search strategy

We performed a comprehensive literature search for relevant studies evaluating the association between hyperuricemia and CAC from four major electronic databases: MEDLINE, EMBASE, the Cochrane Library, and EBSCO (CINAHL), using the following heading MeSH terms and keywords: [uric acid OR hyperuricemia OR urate] AND [Coronary artery calcification OR coronary calcification OR coronary artery calcium score OR coronary artery calcium scoring OR Coronary calcium OR Coronary calcium score OR Coronary calcium scoring OR coronary artery calcification OR coronary calcification OR coronary artery calcium]. The search included all studies published up to 2 June 2019, with no language restriction. The studies were manually screened. A full electronic search strategy (no limits) performed in MEDLINE can be reviewed in the Supporting Information Appendix.

2.2 | Study eligibility

The study inclusion criteria were: (a) adult subjects; (b) describing the association between hyperuricemia and CAC; (c) the definition of CAC presence determined as the Agatston score over 0; (d) CAC association between hyperuricemia and CAC; (e) the definition of SUA levels. The cutoff values for hyperuricemia differed among studies (Table 1).

2.3 | Study selection

Two reviewers (LL and XHH) independently screened the titles and abstracts to determine the inclusion of the studies. Full texts of the selected studies were read to further screen for eligible studies. Abstracts from conference or meetings were used to find the related published articles. Attempts were made to contact the original authors for additional details if necessary. Any discrepancy was resolved by a third reviewer (HLB) to reach a consensus.

2.4 | Data abstraction and quality assessment

Two reviewers (LL and XHH) independently extracted all data by using a standardized data abstraction excel file to retrieve information about studies features (first authors, publication years, publishing journals, and study types), participants information (gender, geographical location, sample size, and basic diseases), cutoff levels for hyperuricemia, outcome definition, confounders, duration of follow-up, the frequency of CAC presence, and ORs. The primary outcome was the risk estimate for the association between hyperuricemia and CAC. The secondary outcome was the risk for CAC progression. Given only observational studies were found, the Newcastle-Ottawa Scale was applied for quality assessment based on three components as follows: selection of the study groups (0-5 points for cross-sectional study, 0-4 points for cohort study and case-control study), comparability of study groups (0-2 points), and ascertainment of the interest outcome (0-3points). The score ranges from 0 to 10 points, with a higher score indicating better methodological quality. Discrepancies were resolved by third reviewer (HLB) and fourth reviewer (ZYL).

2.5 | Statistical analysis

The conventional unit (milligram per deciliter) was used for all SUA levels. A conversion rate of 0.01681 (1 μmol/L = 0.01681 mg/dL) was used to standardize all SUA levels. The cutoff values for hyperuricemia differed among studies (Table 1). The score ranges from 0 to 10 points, with a higher score indicating better methodological quality. Discrepancies were resolved by third reviewer (HLB) and fourth reviewer (ZYL).

Based on the frequency of CAC presence (CAC score > 0) (among both hyperuricemia and normouricemia groups) for each study, the pooled estimates of ORs and 95% confidence intervals (CIs) were calculated to evaluate the crude relationship between SUA and CAC. As for the confounders, adjusted ORs were used to evaluate the association of SUA as a categorical variable for CAC prevalence. The prediction of SUA on CAC progression was performed by pooling adjusted ORs.

We evaluated the presence of heterogeneity across trials by using the I² statistic. If I² < 50% and P value is >.1, heterogeneity is acceptable. If I² > 50% and P value is <.1, we would adopt random effect or a meta-regression method to find sources for the obvious heterogeneity. To assess the potential publication bias, we conducted the visually symmetric funnel plot and quantified Egger test.
| First author                  | Year | Journal                          | Age (year) | Sample size (%men) | Participants                                                                 | Hyperuricemia definition (mg/dL) | Confounding factors                                                                 | Outcome definition | Type of study         | NOS score | Follow-up duration |
|------------------------------|------|----------------------------------|------------|--------------------|-------------------------------------------------------------------------------|-------------------------------|----------------------------------------------------------------------------------|-------------------|----------------------|------------|----------------------|
| Raul D. Santos               | 2007 | *American Journal of Cardiology* | 48 ± 7     | 371 (100)          | Brazil man, white, nondiabetic subjects free of known CHD                    | ≥7.1                           | Age, SBP, waist circumference, HDL-C, TG, glucose, smoking, physical activity, and WBC count, MetS | CAC score > 0     | Cross-section        | 9 (4/3)   | —                    |
| Ticiana C. Rodrigues         | 2010 | *Diabetes Care*                  | 38.5 ± 8.3 | 969 (46)           | United States, individuals asymptomatic for CAD                              | Per 1 mg/dL increase           | Age, gender, type 1 diabetes, baseline CVS, HTN, smoking, HDL-C, LDL-C            | Progression of CAC | Retrospective cohort | 9 (4/2/3) | 6.0 ± 0.5 years     |
| Eswar Krishnan               | 2011 | *Arthritis Research and Therapy* | 40 ± 4     | 2498 (48)          | US young adults free of CKD, diabetes from CARDIA trial                      | M: > 6.7, F: > 4.7             | Age, gender, race, HDL-C, LDL-C, TG, smoking, BP class, MetS, CRP, waist circumference, alcohol use, creatinine, and serum albumin | CAC score > 0     | Cross-section        | 9 (4/2/3) | —                    |
| Cao Hui-li                   | 2013 | *Chinese Journal of Epidemiology* | 60.3 ± 11.02 | 903 (48)          | China, natural population in Beijing                                          | ≥7.1                           | Gender, age, BMI, creatinine, hsCRP, SBP, DBP, FPG, TC, TG, HDL–C, smoking, alcohol use | CAC score > 0     | Cross-section        | 9 (4/2/3) | —                    |
| Aslı İnci Atar               | 2013 | *The Anatolian Journal of Cardiology* | 53.6 ± 10.5 | 442 (77)          | Turkey, suspected CHD with a low-intermediate risk for CAD                   | >5.6 per 1 mg/dL increase      | Age, smoking and 10-year total risk of Framingham risk score                        | CAC score > 0     | Case control         | 8 (4/2/2) | —                    |
| Chagai Grossman              | 2014 | *The Journal of Clinical Hypertension* | 55.5 ± 7.3 | 663 (85)          | Israel, men above 40 and women above 50, free of CVD                        | >6.1                           | Age, gender, HTN, eGFR, BMI, diabetes, hyperlipidemia                              | CAC score > 0     | Prospective cross-section | 9 (4/2/3) | —                    |
| Petter Bjornstad             | 2014 | *Acta Diabetologica*             | 36.5 ± 9   | 652 (46)          | United States, asymptomatic for CVD, with or without type 1 diabetes         | Per 1 mg/dL increase           | Age, diabetes duration, HbA1c, HDL-C, SBP, DBP, and antihypertensive medications | CAC progression, CAC score > 0 | Prospective cohort | 9 (4/2/3) | Average 6.1 years    |
| Richard Y. Calvo             | 2014 | *American Journal of Cardiology* | 62.2 ± 6.4 | 368 (0)           | United States, Filipino women, and Non-Hispanic, white women                 | Per 1 mg/dL increase           | Age, follow-up time, HTN, diabetes, statin use and visceral adiposity, estrogen use | CAC progression, CAC score > 0 | Retrospective cohort | 9 (4/2/3) | Average 4.6 years    |
| Rehan Malik                  | 2016 | *Aging Clinical and Experimental Research* | 84.5 ± 4.2 | 208 (21)          | Brazilian octogenarians (C80 years) free                                    | —                              | Gender, BMI, SBP, DBP, antihypertensive treatment, diabetes, use of oral hypoglycemic agents, TC, | CAC score > 0     | Prospective cross-section | 9 (4/2/3) | —                    |

(Continues)
A two-tailed *P* value < .05 was considered statistically significant. All the statistical analyses were performed in Stata 15.1 (Stata Corp, College Station, Texas).

### RESULTS

#### 3.1 Search and selection of studies

The initial electronic database search identified 267 articles and there were 77 duplicates. A total of 124 irrelevant articles were excluded after screening by titles and abstracts. One case report and three letters were excluded. After reading the remaining 62 articles in full text, 11 studies were excluded. A total of 110 participants were included in the meta-analysis. The characteristics of the included studies and their participants are summarized in Table 1. Of the 11 included studies (all observational), four were conducted in the United States, one in Europe, three in Asia, and three in Latin America. The sample size of the studies ranged from 208 to 3753 participants. The average duration of follow-up was 4.6 years in men and from 4.7 to 7.1 years in women. There were seven studies with gender-specific cutoffs. The association between hyperuricemia and CAC was reported in one case control study, 17 cross-sectional and seven prospective studies. All of the selected studies were assessed as high quality according to the NOS scale (10 studies have NOS scores as 9 and 1 study as 8; see Table 1).

### Table 1

| First author | Year | Journal | Sample size (%men) | Participants | Hyperuricemia definition (mg/dL) | Confounding factors | Outcome definition | Type of study | NOS score | Follow-up duration |
|--------------|------|---------|--------------------|--------------|----------------------------------|---------------------|-------------------|---------------|-----------|-------------------|
| Loretta Zsuzsa Kiss | 2018 | Journal of Cardiovascular Translational Research | 60 ± 10.9 | 281 (41) | Hungarian healthy adults | Gender, BMI, Diabetes, age, smoking, creatinine clearance | CAC score > 0 | Cross-section | 9 (4/2/3) | – |
| Paulo H. Harada | 2019 | Journal of Cardiology | 49 (44-55) | 3753 (46) | Brazilian, Sao Paulo site participants of the ELSA-Brasil cohort | Age, gender, race/ethnicity, family history of CAD, alcohol use, smoking, physical activity, waist circumference, diabetes, HTN, HDL-C, TG, hsCRP | CAC score > 0 | Cross-section | 9 (4/2/3) | – |

Abbreviations: BMI, body mass index; CAC, coronary artery calcification; CAD, coronary artery disease; CHD, coronary heart disease; CKD, chronic kidney disease; CRP, C reactive protein; CVD, cardiovascular disease; CVS, calcium volume scores; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; hsCRP, high sensitivity C reactive protein; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; WBC, white blood cell.
FIGURE 2  Forest plot of association between hyperuricemia and CAC prevalence after one article deleted. CAC, coronary artery calcification

FIGURE 3  Forest plot of pooled adjusted ORs for CAC presence in the highest SUA category. CAC, coronary artery calcification; ORs, odds ratios
3.3 | Crude association between SUA and CAC incidence

Five studies were selected to analyze the association between CAC incidence and SUA level. Meta-analysis showed that patients in the high SUA group had a higher risk of CAC incidence (n = 436, 63%) than patients in the normouricemia group (n = 897, 46%) using a random model (OR: 1.98, 95% CI: 1.55-2.55). \( I^2 \) was 43.5% (<50%). In order to reduce the heterogeneity, the data with the minimal threshold level of hyperuricemia (more than 6 mg/dL or 357 \( \mu \)mol/L) were used for further analysis. There was no change in the pooled result (OR: 1.806, 95% CI: 1.491-2.186) under fixed model with no observed heterogeneity (\( I^2 \) = 0%, \( P = .415 \)) (Figure 2) after one study was excluded because the authors defined hyperuricemia level as 5.6 mg/dL (333 \( \mu \)mol/L). The funnel plot was symmetrical and Egger test \( P \) value was .782, meaning no significant publication bias.

3.4 | Risk prediction of high SUA on CAC presence

The adjusted ORs extracted from seven studies were analyzed with SUA as a categorical variable. Three studies used tertile for SUA stratification and three studies used quartile, while only one study analyzed SUA concentrations strata as dichotomy. In the highest SUA category, the pooled estimated OR was 1.48 (95% CI: 1.23-1.79) with no observed heterogeneity (\( I^2 = 0\% \), \( P = .415 \)) (Figure 3). The funnel plot was symmetrical and result of Egger test was not statistically significant (\( P = .085 \)) which suggested that there was no serious small studies effect.

3.5 | Association between SUA and CAC progression

The pooled evaluation of adjusted ORs for CAC progression based on three cohort studies was 1.31 (95% CI: 1.15-1.49) with no observed heterogeneity (Figure 4). The average follow-up year ranged from 4.6 to 6.1. The funnel plot was asymmetrical and Egger test result showed small size publication bias (\( P = .013 \)).

4 | DISCUSSION

The results of our meta-analysis provided a new insight into the association between SUA and CAC development in subclinical patients. We found that the odds of developing CAC were increased by 81% in patients with hyperuricemia. When the highest SUA category was compared with the lowest SUA category, the pooled adjusted estimate showed that the risk of CAC presence was almost 1.5-fold. Moreover, the risk of CAC progression was increased by up to 1.31-fold with an average follow-up duration ranged from 4.6 to 6.1 years.

SUA, a novel risk factor, has been associated with the development of subclinical cardiovascular disease (CVD). In addition, the risk of mortality and severity of CHD are increased in patients with hyperuricemia. The results from this meta-analysis support these findings as we have found that SUA is associated with subclinical CAC. There are several possible mechanisms that can explain the association. In vitro, uric acid has stimulated primary vascular smooth muscle cells (VSMC) to produce inflammatory cyclooxygenase-2 and superoxide anion which contribute to the pathogenesis of atherosclerosis.
been shown to cause premature atherosclerosis by disturbing lipid metabolism, promoting the proliferation of VSMCs, and more importantly, activating inflammation.34 Additionally, aortic calcification has occurred earlier (more severe) in the high uric acid group compared with the normal diet group and high fat diet group. It is of interest to note the longer exposure to hyperuricemia, the more severe the calcium deposition in the medial layer of blood vessels.34 In a middle cerebral artery occlusion rat model conducted by Song and Zhao,35 uric acid feeding has led to endothelial cell death and significant drop of nitric oxide which have initiated and accelerated the atherosclerosis progression.

Since hyperuricemia is a risk factor for early stage of atherosclerosis, therapeutic agents targeting lower uric acid levels would be of interest. Colchicine is widely used, well tolerated, and effective for prevention and treatment of acute gout which is due to hyperuricemia. As uric acid crystals and cholesterol crystals are activated by the same pathway in the pathogenesis of atherosclerosis, colchicine can play a protective role in CVD patients36 by rapidly reducing high sensitivity C reactive protein (hs-CRP),37 stabilizing the atherosclerosis plaque,38 and reducing cardiovascular events at low dose.39 Nevertheless, xanthine oxidase inhibitors, which are another agents used to lower SUA level, have not reduced mortality in patients with CVD.40 Future studies are needed to evaluate the efficacy of different types of uric acid lowering drugs on reducing the risk of CAC development and progression.

There were several limitations in this meta-analysis. First, a strong publication bias was observed with regards to CAC progression in only three cohort papers. The small sample size publication bias and null results unpublished bias may explain this publication bias. Second, the vast majority of selected 11 studies were conducted in developed countries. The results from this meta-analysis may not be applied to under-developed countries where different diet and lifestyle would affect the association. Third, although a multivariable adjustment was conducted in most of the included studies, confounding effects from other unadjusted risk factors may exist. Notably, none of the included studies has been adjusted for diet, which significantly influences the SUA level. Despite these limitations, this is the first meta-analysis to analyze the relationship between hyperuricemia and CAC.

5 | CONCLUSION

This systematic review and meta-analysis showed an association between hyperuricemia and increased risk of CAC development and CAC progression in asymptomatic patients. Our findings suggested that patients with hyperuricemia should be monitored closely for coronary atherosclerosis.

AUTHOR CONTRIBUTIONS

W.H.L. and Z.Q.Q. conceived and conceptualized the research idea. L.L., X.H.H. and H.L.B. performed the screening, full text assessment, quality assessment and data extraction and Z.Q.Q. approved the data. L.L. and X.H.H. did data analyses, Z.Y.L. contributed and Z.Q.Q. supervised the analysis. L.L. and X.H.H. framed the results and drafted the manuscript. K.R.B. and W.T. made revisions on the draft and approved the final version. Z.Q.Q. supervised the whole study process and is guarantor.

ORCID

Ling Liang https://orcid.org/0000-0003-3772-6262
Xianghua Hua https://orcid.org/0000-0002-6433-5374
Kevin R. Bainey https://orcid.org/0000-0003-0081-8649
Yanlin Zhang https://orcid.org/0000-0001-9107-8994
Wayne Tymchak https://orcid.org/0000-0003-3621-0520
Zhongguan Qi https://orcid.org/0000-0002-5414-9148
Weihua Li https://orcid.org/0000-0002-9344-8319
Hoa Linh Banh https://orcid.org/0000-0002-5976-7201

REFERENCES

1. Shekar C, Budoff M. Calcification of the heart: mechanisms and therapeutic avenues. Expert Rev Cardiovasc Ther. 2018;16(7):527-536. https://doi.org/10.1080/14779072.2018.1484282.
2. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827-832. https://doi.org/10.1016/0735-1097(90)90282-T.
3. LaMonte MJ, Fitzgerald SJ, Church TS, et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. Am J Epidemiol. 2005;162(5):421-429. https://doi.org/10.1093/aje/kwi228.
4. Greenland P, Labree L, Azen SP, Doherty TM, Deltran RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210-215. https://doi.org/10.1001/jama.291.2.210.
5. Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol. 2015;77:323-345. https://doi.org/10.1146/annurev-physiol-021113-170343.
6. Papéžíková I, Pekarová M, Kolárůvá H, et al. Uric acid modulates vascular endothelial function through the down regulation of nitric oxide production. Free Radic Res. 2013;47(2):82-88. https://doi.org/10.3109/10715762.2012.747677.
7. Säutin YJ, Johnson RG. Uric acid: the oxidant-antioxidant paradox. Nucleosides, Nucleotides and Nucleic Acids. 2008;276(7-8):608-619. https://doi.org/10.1080/15257770802138558.
8. White J, Sofat R, Hemani G, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2016;4(4):327-336. https://doi.org/10.1016/S2213-8587(15)00386-1.
9. Ndrepepa G, Braun S, Haase HU, et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol. 2012;109(9):1260-1265. https://doi.org/10.1016/j.amjcard.2011.12.018.
10. Duran M, Kalay N, Akpek M, et al. High levels of serum uric acid predict severity of coronary artery disease in patients with acute coronary syndrome. Angiology. 2012;63(6):448-452. https://doi.org/10.1177/0003319711426868.
11. Ndrepepa G, Braun S, King L, et al. Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism. 2012;61(12):1780-1786. https://doi.org/10.1016/j.metabol.2012.05.014.
12. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomization analysis of two large cohorts. BMJ. 2013;347(7919):1-10. https://doi.org/10.1136/bmj.f4262.
13. Keenan T, Zhao W, Rasheed A. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization
study. J Am Coll Cardiol. 2016;37(4):407-416. https://doi.org/10.1186/09031936.00063810.

14. Cao HL, Lv B, Chen XB, et al. Relation between uric acid and coronary artery calcification: a community-based cross-sectional survey among Beijing national population. Zhonghua Liu Xing Bing Xue Za Zhi. 2013;34(6):566-568. https://doi.org/10.3760/cma.j.issn.0254-4350.2013.06.006.

15. Kiss LZ, Bagyura Z, Csobay-Novak C, et al. Serum uric acid is independently associated with coronary calcification in an asymptomatic population. J Cardiovasc Transl Res. 2018;12:204-210. https://doi.org/10.1007/s12265-018-9843-8.

16. Kim HHJ, Kim SHS, Choi AR, et al. Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: a single-center cross-sectional study. Medicine (Baltimore). 2017;96(14):1-7. https://doi.org/10.1097/MD.0000000000006656.

17. Calvo RY, Araneta MRG, Kritz-Silverstein D, Laughlin GA, Barrett-Connor E. Relation of serum uric acid to severity and progression of coronary artery calcium in postmenopausal White and Filipino women (from the rancho Bernardo study). Am J Cardiol. 2014;113(7):1153-1158. https://doi.org/10.1016/j.amjcard.2013.12.022.

18. Bjornstad P, Maahs DM, Rivard CJ, et al. Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes study. Acta Diabetol. 2014;51(5):783-791. https://doi.org/10.1007/s00592-014-0611-1.

19. Malik R, Aneni EC, Shahrayar S, et al. Elevated serum uric acid is associated with vascular inflammation but not coronary artery calcification in the healthy octogenarians: the Baltimore study on healthy aging. Aging Clin Exp Res. 2016;28(2):359-362. https://doi.org/10.1007/s40520-015-0395-3.

20. Neogi T, Terkelbaum R, Ellison RC, Hunt S, Zhang Y. Serum urate is not associated with coronary artery calcification: the NHLBI family heart study. J Rheumatol. 2011;38(1):111-117. https://doi.org/10.3899/jrheum.100639.

21. Gensler DI, Ms PD, Jesse A, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012. https://doi.org/10.1001/jama.283.15.2008.

22. Pereira AC, Gomez LM, Bittencourt MS, et al. Age, gender, and race-based coronary artery calcium score percentiles in the Brazilian longitudinal study of adult health (ELSA-Brasil). Clin Cardiol. 2016;39(6):352-359. https://doi.org/10.1002/clc.22539.

23. Hokanson JE, MacKenzie T, Kinney G, et al. Evaluating changes in coronary artery calcification: an analytic method that accounts for inter-scan variability. AJR Am J Roentgenol. 2004;182(5):1327-1332. https://doi.org/10.2214/ajr.182.5.1821327.

24. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605. https://doi.org/10.1007/s10654-010-9491-z.

25. Rodrigues TC, Maahs DM, Johnson RJ, et al. Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease. Diabetes Care. 2010;33(11):2471-2473. https://doi.org/10.2337/dc10-1007.

26. RD S, Nasir K, Orakzai R, et al. Relation of uric acid levels to presence of coronary artery calcium detected by electron beam tomography in men free of symptomatic myocardial ischemia with versus without the metabolic syndrome. Am J Cardiol. 2007;99(1):42-45. https://doi.org/10.1016/j.amjcard.2006.07.057.

27. Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis—data from a prospective observational cohort study. Arthritis Res Ther. 2011;13(2):R66. https://doi.org/10.1186/ar3322.

28. Grossman C, Shemesh J, Koren-Morag N, Bornstein G, Ben-Zvi I, Grossman E. Serum uric acid is associated with coronary artery calcification. J Clin Hypertens. 2014;16(6):424-428. https://doi.org/10.1111/jch.12313.

29. Harada PH, Bensenor IM, Bittencourt MS, et al. Composite acute phase glycoproteins with coronary artery calcification depends on metabolic syndrome presence - The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Cardiol. 2019;73(5):408-415. https://doi.org/10.1016/j.jjcc.2018.09.006.

30. Atar AI, Yilmaz OC, Alkın K, Selcoki Y, Er O, Eryonyucu B. Serum uric acid level is an independent risk factor for presence of calcium in coronary arteries: an observational case-controlled study. Anadolu Kardiyol Dergisi/the Anatol J Cardiol. 2013;13(2):139-145. https://doi.org/10.5152/akd.2013.039.

31. Andrés M, Quintanilla MA, Sivera F, et al. Silent monosodium Urate crystals are associated with severe coronary calcification in asymptomatic hyperuricemia: an exploratory study. Arthritis Rheumatol. 2016;68(6):1531-1539. https://doi.org/10.1002/acr.39581.

32. Zuo T, Liu X, Jiang L, Mao S, Yin X, Guo L. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016;16(1):1-10. https://doi.org/10.1186/s12872-016-0379-z.

33. Oguz N, Kirca M, Četin A, Yesilkaya A. Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells. J Recept Signal Transduct. 2017;37(5):500-505. https://doi.org/10.1080/10799893.2017.1363050.

34. Liu Z, Chen T, Niú H, et al. The establishment and characteristics of rat model of atherosclerosis induced by hyperuricemia. Stem Cells Int. 2016;2016:1-7. https://doi.org/10.1155/2016/1365257.

35. Song C, Zhao X. Uric acid promotes oxidative stress and enhances vascular endothelial cell apoptosis in rats with middle cerebral artery occlusion. Biosci Rep. 2017;38(3):BSR20170939. https://doi.org/10.1042/bsr20170939.

36. Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262-271. https://doi.org/10.1016/j.atherosclerosis.2017.12.027.

37. Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007;99(6):805-807. https://doi.org/10.1016/j.amjcard.2006.10.039.

38. Vaidya K, Arnold C, Martínez GJ, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. JACC Cardiovasc Imaging. 2018;11(2):305-316. https://doi.org/10.1016/j.jcmg.2017.08.013.

39. Nidorf SM, Eikelboom JW, Budgen CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. https://doi.org/10.1016/j.jacc.2012.10.027.

40. Zhang J, Dierckx R, Mohee K, Clark AL, Cleland JG. Xanthine oxidase model of atherosclerosis induced by hyperuricemia. JACC Cardiovasc Imaging. 2018;11(2):305-316. https://doi.org/10.1016/j.jcmg.2017.08.013.